Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma (NCT03712202)
A Phase 2 Front-Line PET/CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)
🩺 Plain-English Summary (8th-Grade Level)
This phase II trial studies how well brentuximab vedotin and nivolumab work in treating patients with stage I-II classic Hodgkin lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Who can join: Review the eligibility criteria below.
Location: University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
Age range: 16 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- University of Alabama at Birmingham Cancer Center — Birmingham, Alabama
- City of Hope Medical Center — Duarte, California
- University of California San Diego — San Diego, California
- Emory University Hospital/Winship Cancer Institute — Atlanta, Georgia
- Northwestern University — Chicago, Illinois
- University of Chicago Comprehensive Cancer Center — Chicago, Illinois
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana-Farber Cancer Institute — Boston, Massachusetts
- Massachusetts General Hospital — Charlestown, Massachusetts
- Hackensack University Medical Center — Hackensack, New Jersey
- NYP/Weill Cornell Medical Center — New York, New York
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center — Cleveland, Ohio
- Ohio State University Comprehensive Cancer Center — Columbus, Ohio
- University of Pennsylvania/Abramson Cancer Center — Philadelphia, Pennsylvania
- Sarah Cannon Cancer Center — Nashville, Tennessee
- M D Anderson Cancer Center — Houston, Texas
- Huntsman Cancer Institute/University of Utah — Salt Lake City, Utah
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Ann Arbor Stage I Hodgkin Lymphoma
Explore by condition: All Ann Arbor Stage I Hodgkin Lymphoma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.